GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Net Policyholder Benefits/Claims

Biomarin Pharmaceutical (LTS:0HNC) Net Policyholder Benefits/Claims


View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Biomarin Pharmaceutical (LTS:0HNC) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.